Last updated: August 27, 2023
Sponsor: Alexandria University
Overall Status: Completed
Phase
3
Condition
Manic Disorders
Williams Syndrome
Dementia
Treatment
Quatiapine
Haloperidol
Clinical Study ID
NCT05690698
QHMHD
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All patients who are diagnosed with hyperactive form of delirium during their ICU stayusing CAM-ICU tool (the confusion assessment method for the intensive care unit)
Exclusion
Exclusion Criteria:
- Suspected substance-induced delirium
- Previous use of antipsychotics
- Known allergy or intolerance to the study drugs
- Pregnancy or breast feeding
- Acute renal injury
- Hepatic failure
- Inability to tolerate oral drugs
Study Design
Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Quatiapine
Phase: 3
Study Start date:
April 09, 2023
Estimated Completion Date:
July 15, 2023
Study Description
Connect with a study center
Faculty of Medicine, Alexandria University Hospitals
Alexandria,
EgyptSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.